MYGN (Myriad Genetics Corp) Forward P/E Multiple

Myriad - graphic logo of issuer MYGN

Myriad Genetics, Inc. (MYGN) is strengthening its stability by expanding its testing spectrum from oncology to psychiatry to minimize insurance risks. The company's forward P/E ratio confirms this trend, with the value holding at 0.00. Efficiency is driven by the rapid delivery of biomaterials to laboratories, while system reliability is supported by external cloud data storage with full control over the scientific core.

Price to Future Earnings Ratio: myriad.com (MYGN) for 07/04/2022 - 11/15/2026

Analytical breakdowns for Myriad Genetics (MYGN)

- current price and projected stock value:
Stock Quotes Myriad Genetics Corp|MYGN - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Myriad Genetics Corp|MYGN - Enterprise Value
- book capitalization information:
Net Assets per Single Share Myriad Genetics|MYGN - Accounting Capitalization|Market Capitalization to Book Value Ratio myriad.com|MYGN - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Myriad Genetics, Inc.|MYGN - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Myriad|MYGN - Company Cumulative Debt|Debt to Book Capitalization Ratio Myriad Genetics, Inc.|MYGN - Long-Term Debt Volume|Company Short-Term Debts Myriad Genetics|Quick Liquidity myriad.com
- company profitability and valuation multiples indicators:
MYGN - Net Financial Result|Expected Profit Myriad Genetics, Inc.|MYGN - Price to Earnings Ratio|Projected Price to Earnings Myriad Genetics Inc|MYGN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Myriad Genetics|MYGN - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Myriad Genetics|MYGN - Net earnings per share for the last four quarters|Quarterly EPS earnings growth myriad.com|MYGN - Earnings growth in current year|Earnings growth forecast for next year Myriad Genetics, Inc.
- sales revenue and business income indicators:
MYGN - Company Sales Volume|Company Future Sales Volume Myriad Genetics Corp|MYGN - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Myriad|MYGN - Revenue Growth Rate YoY (Last Twelve Months)
Analysis of all company metrics:MYGN Myriad
Signature product of myriad.com

The forward P/E reflects the market value of the business relative to its expected annual earnings. For Myriad Genetics, Inc. (MYGN), this calculation links market capitalization to the monetization of its leadership in high-precision genetics. By analyzing the company's projected price-to-earnings multiple on GURU.Markets, an investor can identify valuation deviations from the fundamental trend. Low values may indicate an undervaluation of a brand that enjoys the trust of oncologists, allowing for the differentiation of sustainable growth from temporary market fluctuations.

Main competitors

Forward P/E Multiple CAI|Guardant360 - Price to Future Earnings Ratio|Forward P/E Multiple VCYT (Veracyte Diagnostics)|Forward P/E Multiple celcuity.com CELC|GRAL - Future Price to Earnings|CSTL (Castle Biosciences, Inc.) - Price to Future Earnings Ratio|Burning Rock Biotech Ltd. (BNR) - Future Price to Earnings|VolitionRx Ltd (VNRX) - Forward P/E Multiple|Future Price to Earnings Biodesix, Inc.|Future Price to Earnings PRPO|Projected Price to Earnings CHEK (Check-Cap Ltd.)|MYNZ - Projected Price to Earnings Ratio|Forward P/E Multiple OCX (OncoCyte Inc)